Amgen

...2007- 037273), the Swedish Medical Research Council (8691), the Knut and Alice Wallenberg Foundation, and AstraZeneca AB. Other than Amgen, which provided genotyping and collaborative scientific support, the funders had no role in study design,...

In this article: Lipoprotein, Low-density lipoprotein, Very low density lipoprotein, Cholesterol, High-density lipoprotein, Medical advice, and PLoS Genetics

...million to date, and has numerous customers, including the national Centers for Disease Control and Prevention, Genome Quebec, and Amgen. The company expects to soon announce a new diagnostic lab customer that expects to store 750,000...

In this article: GenVault, Carbon footprint, RAND Corp., Centers for Disease Control and Prevention, San Diego, Carlsbad, CA, and United States

...well as for its potential to delay bone metastases and inhibit and treat bone destruction across many stages of cancer. About Amgen Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer...

In this article: Thrombocytopenia, Denosumab, Cancer, European Union, FDA, Breast cancer, United States, Corticosteroid, and Rheumatoid arthritis

...advisory board, sparing them from future potential payment cuts. BRAND BIOLOGIC DRUGMAKERS * Biological drugmakers such as Amgen Inc, Roche's Genentech unit maintained their 12-year period of exclusive sales for brand-name drugs...

In this article: Medicare, Tax, Genentech, Medicare and Medicaid, America's Health Insurance Plans, Medicaid, Breast implant, Mentor, and Universal Health Services Inc

...in milestone payments Drugmaker ImmunoGen Inc <IMGN.O> said it licensed its technology to develop anti-cancer drugs to Amgen Inc <AMGN.O> for a $1 million upfront payment. ImmunoGen is also entitled to receive milestone payments of up...

In this article: Amgen Inc, Cancer, Nasdaq, and Bangalore

WALTHAM, Mass. (AP) - ImmunoGen Inc. said Thursday that Amgen Inc. licensed rights to a second potential cancer-treatment from the company for $1 million upfront. Immunogen develops cancer treatments using its Tumor-Activated Prodrug, or...

In this article: Amgen Inc., Cancer, and Massachusetts

Waltham, MA-based ImmunoGen (NASDAQ: IMGN) said today that Amgen has purchased a second license to develop a treatment that uses ImmunoGen's technology for linking targeted antibodies to cell-killing agents that make them more potent.

In this article: All rights reserved, WordPress, Twitter, Nasdaq, and Xconomy

...negotiation under the Medicare plan for the elderly. Biotechnology companies also can rest easy, as companies such as Amgen Inc <AMGN.O>, Roche Holding AG <ROG.VX> maintain their 12-year period of exclusive sales for brand-name drugs...

In this article: Tax, Allergan Inc, Medicare, Botox, Senate Finance Committee, and Revenue

...regarding presentation time, webcast availability, and webcast links are available on Amgen's Investor Relations Events Calendar. About Amgen Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A...

In this article: Cancer, Rheumatoid arthritis, Nasdaq, New York City, and California

...to Present at 18th Annual Credit Suisse Healthcare Conference THOUSAND OAKS, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the 18th Annual Credit Suisse Healthcare Conference on Thursday, Nov. 12,...

In this article: Credit Suisse, Cancer, Rheumatoid arthritis, Nasdaq, and Phoenix, Ariz